Research programme: urological disorder therapeutics - Imprimis Pharmaceuticals

Drug Profile

Research programme: urological disorder therapeutics - Imprimis Pharmaceuticals

Alternative Names: Defeat IC™

Latest Information Update: 25 Nov 2013

Price : $50

At a glance

  • Originator Imprimis Pharmaceuticals
  • Class Anticoagulants; Antithrombotics; Small molecules; Vascular disorder therapies; Vasodilators; Xanthines
  • Mechanism of Action Phosphoric diester hydrolase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Peyronie's disease

Most Recent Events

  • 07 Nov 2013 Preclinical trials in Peyronie's disease in USA (Intracavernous)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top